Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer

Lu, XT; Wang, JB; Wang, CY; Liang, J; Zhou, ZM; Chen, DF; Feng, QF; Xiao, ZF; Hui, ZG; Lu, JM; Zhang, T; Liu, WY; Wang, JY; Wang, X; Deng, L; Zhai, YR; Bi, N; Wang, LH

Bi, N (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Radiat Oncol, Natl Canc Ctr,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China.;Wang, LH (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Radiat Oncol, Natl Canc Ctr,Canc Hosp, 113 Baohe Rd, Shenzhen, Guangdong, Peoples R China.;Wang, LH (通讯作者),Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, 113 Baohe Rd, Shenzhen, Guangdong, Peoples R China.

CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022; 16 ():

Abstract

BACKGROUND: EGFR tyrosine kinase inhibitor (TKI) is recommended as the first-line therapy for patients with EGFR-mutant metastatic non-small cell lung......

Full Text Link